Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has shared an announcement.
Biocytogen Pharmaceuticals has announced the composition of its board of directors, detailing the roles and functions of each member. This update on the board’s structure, including the establishment of four committees, is significant for stakeholders as it reflects the company’s strategic focus on governance and operational oversight.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a joint stock company incorporated in China, focusing on the pharmaceutical industry. The company is involved in developing innovative drugs and therapies, leveraging advanced biotechnological research and development.
Average Trading Volume: 523,150
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.78B
Learn more about 2315 stock on TipRanks’ Stock Analysis page.